UY38934A - Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica - Google Patents

Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica

Info

Publication number
UY38934A
UY38934A UY0001038934A UY38934A UY38934A UY 38934 A UY38934 A UY 38934A UY 0001038934 A UY0001038934 A UY 0001038934A UY 38934 A UY38934 A UY 38934A UY 38934 A UY38934 A UY 38934A
Authority
UY
Uruguay
Prior art keywords
glucopyranosidase
glucoprotein
spirocyclic
deoxy
acetamide
Prior art date
Application number
UY0001038934A
Other languages
English (en)
Spanish (es)
Inventor
Zhili Xin
Nathan Genung
M Guckian Kevin
Jeffrey Vessels
Lei Zhang
Ryan Gianatassio
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of UY38934A publication Critical patent/UY38934A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001038934A 2019-10-29 2020-10-28 Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica UY38934A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962927268P 2019-10-29 2019-10-29

Publications (1)

Publication Number Publication Date
UY38934A true UY38934A (es) 2021-05-31

Family

ID=73554493

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038934A UY38934A (es) 2019-10-29 2020-10-28 Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica

Country Status (8)

Country Link
US (1) US12565504B2 (enExample)
EP (1) EP4051682A1 (enExample)
JP (1) JP2023501949A (enExample)
CN (1) CN114929709B (enExample)
AR (1) AR120324A1 (enExample)
TW (1) TW202130643A (enExample)
UY (1) UY38934A (enExample)
WO (1) WO2021086966A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022095971A1 (zh) * 2020-11-06 2022-05-12 上海医药集团股份有限公司 一种螺杂环类化合物、其制备方法及应用
WO2025247394A1 (zh) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用
CN119569746B (zh) * 2025-02-06 2025-05-13 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
WO2007063385A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
ATE486877T1 (de) 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
WO2010141074A2 (en) * 2009-06-01 2010-12-09 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
AU2012298949B2 (en) * 2011-08-25 2016-09-22 Merck Patent Gmbh Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
PT2970272T (pt) * 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
NZ727185A (en) * 2014-06-24 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN107912040B (zh) * 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
US11186564B2 (en) * 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
AU2018216040A1 (en) 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds

Also Published As

Publication number Publication date
WO2021086966A1 (en) 2021-05-06
TW202130643A (zh) 2021-08-16
US12565504B2 (en) 2026-03-03
US20230060003A1 (en) 2023-02-23
CN114929709A (zh) 2022-08-19
EP4051682A1 (en) 2022-09-07
AR120324A1 (es) 2022-02-09
CN114929709B (zh) 2024-08-30
JP2023501949A (ja) 2023-01-20

Similar Documents

Publication Publication Date Title
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CR20150454A (es) Compuestos amida para el tratamiento de vih
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX374794B (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
UY38498A (es) Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20251223